Immunovant, Inc. IMVT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s operating cash flow?
- Immunovant, Inc. (IMVT) reported operating cash flow of -$95.06M in Q1 2026.
- How has Immunovant, Inc.'s operating cash flow changed year-over-year?
- Immunovant, Inc.'s operating cash flow increased by 14.1% year-over-year, from -$110.64M to -$95.06M.
- What is the long-term trend for Immunovant, Inc.'s operating cash flow?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s operating cash flow has grown at a 40.0% compound annual growth rate (CAGR), from -$106.11M to -$407.31M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.